Cancer antigen 125 levels in patients with ascites

Turkish Journal of Gastroenterology

Volumn 14, Issue 4, 2003, Pages 257-261

  Algan Öcal, Pelin ^a   Akşahin, Arzu ^a   Çetin, Türkan ^a   Yildirim, I Safa ^a  

^a Neurosurgery Clinic   (Turkey)

Author keywords

Ascites; Cancer antigen 125; Tumor markers

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CA 125 ANTIGEN;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIGEN DETECTION; ARTICLE; ASCITES; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD SAMPLING; CORRELATION ANALYSIS; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; ECHOGRAPHY; FEMALE; HOSPITALIZATION; HUMAN; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MOLECULAR WEIGHT; PHYSICAL EXAMINATION; TURKEY (REPUBLIC);

ADOLESCENT; ADULT; AGED; ASCITES; CA-125 ANTIGEN; FEMALE; HUMANS; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 43549112709     PISSN: 13004948     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Kabawat SE, Bast RC Jr, Bhan AK, et al. Tissue distribution of a coelomic-epithelium-related antigen recognized by the monoclonal antibody OC125. Int J Gynecol Pathol 1983; 2: 275-85.
2. Bast RC Jr, Freeney M, Lazarus H, et al. Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest 1981; 68: 1331-7.
3. Kabawat SE, Bast RC Jr, Welch WR, et al. Immunopathologic characterization of a monoclonal antibody that recognizes common surface-antigens of human ovarian tumors of serous, endometroid, and clear cell types. Am J Clin Pathol 1983; 79: 98-104.
4. Bast RC, Klug TL, St John E, et al. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med 1983; 309: 883-7.
5. Talbot RW, Nagorney DM, Pemberton JH, et al. Comparison of portal and peripheral blood levels of carcinoembryonic antigen, CA 19-9, and CA 125 tumor-associated antigens in patients with colorectal and pancreatic cancer. Cancer Res 1989; 49: 542-3.
6. Patsner B, Mann WJ. Use of serum CA-125 in monitoring patients with uterine sarcoma. A preliminary report. Cancer 1988; 62: 1355-8.
7. Jalanko H, Haglund C, Roberts PJ, et al. Tumor markers in gastrointestinal cancers. In: Holmgerm J (ed). Tumor marker antigens. Lund: Studentlitteratur, 1985: 114-22.
8. Ruibal A, Encabo G, Miralles EM, et al. CA125 seric levels in human clinical practice. Our experience in 1542 cases. International Meeting on Monoclonal Antibodies in Oncology: Clinical applications. Nantes France, 1984.
9. Sakamoto K, Haga Y, Yoshimura R, et al. Comparative effectiveness of the tumour diagnostics, CA19-9, CA 125 and carcinoembryonic antigen in patients with disease of digestive system. Gut 1987; 28: 323-9.
10. Bergmann JF, Bidart JM, George M, et al. Elevation of CA 125 in patients with benign and malignant ascites. Cancer 1987; 59: 213-7.
11. Eerdekends MW, Nouwen EJ, Pollet DE, et al. Placental alkaline phosphatase and cancer antigen 125 in sera of patients with benign and malignant disease. Clin Chem 1985; 31: 687-90.
12. Touitou Y, Bogdan A. Tumor markers in nonmalignant disease. Eur J Cancer Clin Onkol 1988; 24: 1083-91.
13. Halila H, Stenman UH, Seppala M. Ovarian cancer antigen CA125 levels in pelvic inflammatory disease and pregnancy. Cancer 1986; 57: 1327-9.
14. Pittaway DE, Douglas JW. Serum CA125 in women with endometriosis and chronic pelvic pain. Fertil Steril 1989; 51: 68-70.
15. Eisermann J, Collins JL. Enzyme immune assay determination of CA125 in serum, peritoneal fluid, and follicular fluid from women with minimal endometriosis after ovarian hyperstimulation. Fertil Steril 1989; 51: 344-7.
16. Mezger J, Wilmanns W, Lamerz R. Elevated serum CA125 levels in patients with benign ascites or pleural effusions. Tumor Biol 1988; 9: 47-52.
17. Molina R, Filella X, Bruix J, et al. Cancer antigen CA125 in serum and ascitic fluid of patients with liver disease. Clin Chem 1991; 37: 1379-83.
18. Barbieri RL, Niloff JM, Bast RC Jr, et al. Elevated serum concentrations of CA 125 in patients with advanced endometriosis. Fertil Steril 1986; 45: 630.
19. Haga Y, Sakamoto K, Egami H, et al.Clinical significance of serum CA125 values in patients with cancers of the digestive system. Am J Med Sci 1986; 292: 30-4.
20. Ruibal A, Encabo G, Martinez-Miralles E, et al. CA125 seric levels in nonmalignant pathologies. Bull Cancer (Paris) 1984; 71: 145-6.
21. Ruibal A, Siurana R. Evidence of a relationship between high serum CA 125 and liver failure pattern in cirrhotic patients without ascites and jaundice. Int J Biol Markers 1986; 1: 55-6.
22. Ricolleau G, Chatal JF, Fumoleau P, et al. Radioimmunoassay of the CA125 antigen in ovarian carcinomas: advantages compared with CA19-9 and CEA. Tumor Biol 1984; 5: 151-9.
23. Bergmann JF, Beaugrand M, Labadie H, et al. CA 125 (ovarian tumor-associated antigen) in ascitic liver disease. Clin Chim Acta 1986; 155: 163-6.
24. Collazos J, Genolla J, Ailende MT, et al. Serum CA 125 levels in patients with nonmalignant liver disease without ascites. Clin Invest 1993; 71: 239.
25. Haglund C, Kuusela P, Roberts P, et al. Tumor marker CA 125 in patients with digestive tract malignancies. Scand J Clin Lab Invest 1991; 51: 265-70.
26. Collazos J, Genolla J, Ruibal A. CA 125 levels in patients with non-neoplastic liver diseases. A clinical and laboratory study. Scan J Clin Lab Invest 1992; 52: 201-6.
27. Bischof P. What do we know about the origin of CA 125? Eur J Obstet Gynecol Reprod Biol 1993; 49: 93-8.
28. Zuckerman E, Lanir A, Sabo E, et al. Cancer antigen 125: a sensitive marker of ascites in patients with liver cirrhosis. Am J Gastroenterology 1999; 94: 1613-8.
29. Mezger J, Lamerz R, Arnholdt H, et al. Tumor-marker in der diagnostik von aszites- und pleura-punktaten. Onkologie 1986; 9: 11-6.
30. Molina R, Ballesta AM, Casals E, et al. Value of CA 125 antigen as tumor marker: preliminary results. Pro tides Biol Fluids 1985; 32: 613-7.